Sun Pharmaceutical: Halol plant OAI classification a huge risk

Pharmaceuticals Industries (Sun Pharma) Halol plant in Gujarat has been classified as ‘Official Action Indicated’ (OAI) by the United States Food and Drugs Administration (USFDA) after a December 2019 inspection.
OAI means that pending product approval from the facility could be withheld by the regulator. Earlier in December, the plant had been issued Form 483 by USFDA with eight observations. This  has escalated into an OAI classification.

The OAI classification implies interalia that the USFDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved. The company continues to manufacture and distribute existing products for the US market, thereby not likely to have any adverse impact on current business from the facility.

Sun Pharma, committed to being a good manufacturing practice (cGMP) compliant and supplying high-quality products to its customers, will continue to cooperate with the USFDA and undertake all necessary steps to resolve these issues and to ensure that the regulator is completely satisfied with its remedial action.
While the exact share of Halol plant in US exports is not known, analysts estimate its share in total revenues to be in high-single digits.

Earlier in a post-earnings call, Sun Pharma’s managing director and executive director Dilip Shantilal Shanghvi had told analysts that post a warning letter from USFDA, the size of dependence on Halol facility for US exports would have gone down.
Meanwhile, not many new drug filings can be expected from Halol in near term even as future drug approvals from the
plant becomes crucial.
Last December, the USFDA had issued form 483 for its Halol facility with eight observations.

Disclaimer –
This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. The information contained herein is from the public domain or sources believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. Also above note is not a recommendation to Buy or SELL and is only a view based on facts and figures and we will be in no way responsible for any losses incurred by anyone who uses this information to either trade or invests securities mentioned herein.